Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
Five-year follow-up shows pembrolizumab extends life for Chinese lung cancer patients with high PD-L1
This Phase 3 trial evaluated pembrolizumab monotherapy against chemotherapy in Chinese patients with previously untreated locally advanced o…
A five-year look at a Chinese lung cancer trial shows pembrolizumab improved survival compared to chemotherapy for patients with high PD-L1 …
Capivasertib-paclitaxel fails to improve overall survival in metastatic TNBC
New drug combo did not extend life for metastatic triple-negative breast cancer patients in this trial
This phase III RCT in 812 patients with previously untreated metastatic triple-negative breast cancer found that adding capivasertib to pacl…
A large global trial found that adding capivasertib to paclitaxel did not improve overall survival for patients with metastatic triple-negat…
Paclitaxel-coated balloons and sirolimus-eluting stents in noncomplex coronary bifurcation lesions
Drug coated balloons show similar results for certain artery blockages
This randomized noninferiority trial subgroup analysis evaluated 2,257 participants with de novo coronary lesions.
New data suggests drug coated balloons may work as well as traditional stents for specific types of coronary artery blockages.
Camrelizumab plus nab-paclitaxel showed modest activity in previously treated advanced urothelial carcinoma patients
New Treatment Extends Life for Bladder Cancer Patients
This multicenter Phase II study evaluated camrelizumab plus nab-paclitaxel in 60 patients with advanced urothelial carcinoma who progressed …
For years, Mark, 64, thought he’d beaten cancer.
Histology-derived gene-expression signatures predict distant recurrence-free interval and chemotherapy benefit in early breast cancer cohorts
New Tool Predicts Breast Cancer Recurrence From Old Slides
This multi-cohort study evaluated histology-derived gene-expression signatures from routine hematoxylin and eosin slides compared with clini…
A simple AI analysis of old biopsy slides can now predict which breast cancer patients face higher risk of recurrence and who truly benefits…
Phase III trial indicates ultra-low-dose nivolumab may improve survival over chemotherapy in advanced solid tumors
A Tiny Dose of This Cancer Drug Is Outperforming Chemo
This Phase III randomized trial evaluated ultra-low-dose nivolumab against standard chemotherapy in patients with advanced solid tumors prog…
Giving a much smaller dose of a powerful cancer drug can extend life with fewer side effects, making treatment more tolerable and accessible…
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
New Drug Combo Extends Survival for Tough Ovarian Cancer
This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participant…
This new combination offers a meaningful survival boost for women with recurrent ovarian cancer that has become resistant to standard treatm…
Neoadjuvant Chemoimmunotherapy Alters Tumor Microenvironment in Esophageal Cancer
Combination therapy may help overcome resistance in esophageal cancer
This Phase 3 RCT in 55 patients with locally advanced esophageal squamous cell carcinoma compared neoadjuvant chemotherapy alone versus comb…
A small trial suggests combination therapy might help overcome resistance in esophageal cancer by targeting specific immune cells.
High-dose dexamethasone during chemotherapy shows no significant cortisol changes in breast cancer
Chemotherapy Steroids May Not Shut Down Your Body’s Stress System
This prospective pilot study included 47 women with breast cancer receiving paclitaxel and dexamethasone.
This small study suggests that the body’s natural ability to make stress hormones might stay intact during certain chemotherapy regimens, ea…
Envafolimab plus lenvatinib and paclitaxel shows activity in advanced gastric cancer after first-line progression
New Drug Combo Gives Hope for Late-Stage Stomach Cancer
This phase II, single-center, open-label trial evaluated envafolimab combined with lenvatinib and albumin-bound paclitaxel in 30 patients wi…
Imagine a patient who has already tried every standard treatment available.
Relacorilant plus nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer
New Drug Combo Extends Survival for Tough Ovarian Cancer Cases
In a phase 3 randomised controlled trial of 381 patients with platinum-resistant ovarian cancer, relacorilant plus nab-paclitaxel significan…
This combination offers a new, simpler option for patients who have run out of standard treatments.
Case report and literature review on concurrent t-AML and LNTB treated with chemoimmunotherapy
Two Rare Diseases Strike After Lung Cancer Treatment
This case report and literature review describes the management of a 54-year-old male with locally advanced lung squamous cell carcinoma, th…
A lung cancer patient treated with chemo and immunotherapy developed two rare diseases simultaneously: a new blood cancer and tuberculosis.